• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2013 - Product Image

Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2013

  • Published: May 2013
  • 54 pages
  • Global Markets Direct

Thrombocythaemia Myelofibrosis – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Thrombocythaemia Myelofibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocythaemia Myelofibrosis. Thrombocythaemia Myelofibrosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Thrombocythaemia Myelofibrosis.
- A review of the Thrombocythaemia READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Thrombocythaemia Myelofibrosis Overview
Therapeutics Development
An Overview of Pipeline Products for Thrombocythaemia Myelofibrosis
Thrombocythaemia Myelofibrosis Therapeutics under Development by Companies
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Thrombocythaemia Myelofibrosis Therapeutics – Products under Development by Companies
Companies Involved in Thrombocythaemia Myelofibrosis Therapeutics Development
Gilead Sciences, Inc.
Novartis AG
Incyte Corporation
Thrombocythaemia Myelofibrosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
panobinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
momelotinib dihydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ruxolitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buparlisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUY-922 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
simtuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-018 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thrombocythaemia Myelofibrosis Therapeutics – Drug Profile Updates
Thrombocythaemia Myelofibrosis – Product Development Milestones
Featured News & Press Releases
Apr 20, 2012: Incyte Announces EU Regulatory Milestone From Novartis For Ruxolitinib
Dec 08, 2010: Incyte Provides Positive Phase II Trial Results Of INCB18424 In Myeloproliferative Neoplasms
Oct 18, 2010: S-BIO's SB1518 Receives Orphan Drug Designation From European Commission For Treatment Of Myelofibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Thrombocythaemia Myelofibrosis, H1 2013
Products under Development for Thrombocythaemia Myelofibrosis – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Gilead Sciences, Inc., H1 2013
Novartis AG, H1 2013
Incyte Corporation, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Thrombocythaemia Myelofibrosis Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Thrombocythaemia Myelofibrosis, H1 2013
Products under Development for Thrombocythaemia Myelofibrosis – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013 20

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos